Adaptive Biotechnologies Corp cotiza a 25.63 USD y tiene una capitalización bursátil de $4.1B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immun…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.25 | $-0.13 | $-0.09 |
| Estimado | $-0.10 | $-0.13 | $-0.16 | $-0.18 |
| Sorpresa | — | -92.3% | +18.8% | +50.0% |
| Métrica | ADPT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 74.2% | 57.0% | +17.2% |
| Operating Margin | -20.6% | -38.6% | +18.0% |
| Net Margin | -21.5% | -33.6% | +12.1% |
| FCF Margin | -17.7% | -13.9% | -3.8% |
| ROE | -27.2% | -40.4% | +13.2% |
| ROA | -11.6% | -32.0% | +20.4% |
| Current Ratio | 3.34 | 2.84 | +0.50 |
| Debt / Equity | 0.58 | 0.28 | +0.30 |